What do you know about colorectal cancer monoantitheticdrugs?

Guide: The number of deaths from colorectal cancer in the national tumor registration area accounted for 7.65 percent of all malignant tumor deathscolorectal cancer (CRC) is derived from the upper skin of the colorectal mucosal membrane, is the most common malignant tumor of the digestive system in clinical practice, the incidence rate of the global malignant tumor ranked third, the mortality rate is the secondHowever, colorectal cancer is one of the few malignant tumors that can be detected early and treated early through screening, so it is necessary to improve understanding of colorectal cancer in lifeThe following is a brief understanding of the basic situation of colorectal cancer through epidemiology, U.SEpidemiologycolorectal cancer is the second most common cause of cancer death in the United States, and the American Cancer Society estimates that about 147,95 million people in the U.Swill be diagnosed with CRC by 2020, and 532,000 will die from the disease, including 179.3 million new cases and 3,640 deaths under the age of 501.1 Overall incidencebetween 2012 and 2016, the incidence of colorectal cancer in the United States was 387 per 100,000, of which 30 per 100,000 were asian/Pacific Islanders, 457 per 100,000 were blacks, and 89 per 100,000 were indigenous AlaskansDuring this period, the incidence of screening-age individuals aged 65 and over continued to decline rapidly, a trend that continued to decline between 2011 and 2016 (3 per cent per year), but the opposite was true for those aged 50 to 64, with the rate increasing by 1 per cent per yearIn general, CRC patients are rapidly moving to young peopleFigure 1 U.Scolorectal cancer incidence varies with age
data source: CA: A Cancer Journal for Clinicians Breast cancer statistics, 20191.2 gender difference
although men (4.4%) and women (4.1%) have a similar lifetime CRC risk, the incidence of men is 31% higher, possibly because women have a longer life expectancy than menThis difference is the largest in rectal tumors and the smallest in near-end colon tumorsIn addition, this gender difference varies greatly with ageFor example, the incidence is quite high among people under 45 years of age, but in the 55-74 age group, the incidence rate is 40 to 50 per cent higher for men than among womenThe reasons for the higher incidence of older men are not entirely clear, but may be due to complex interactions between the accumulation of sex hormones and other factorsFigure 2 U.Scolorectal cancer gender difference statisticsdata source: CA: A Cancer Journal for Clinicians Breast Cancer Statistics, 20191.3Time change trendthe overall incidence of CRC increased in the United States from 1975 to the mid-1980s, but the incidence has generally declined since thenThe decline prior to 2000 was also due to changes in some pathogenic factors (e.g., reduced smoking) and increased use of CRC screening, while the accelerated decline since 2000 was thought to be due to the rapid spread of colonoscopy screening and other screenings for stronger cancer preventionFigure 3 U.Syear-to-year colorectal cancer incidencedata source: CA: A Cancer Journal for Clinicians Breast cancer statistics, 2019II, China EpidemiologyAccording to the China Cancer Registration Annual Report, the incidence of colorectal cancer in China showed a significant upward trend over 10 years, while in terms of mortality, male patients also showed an upward trend year by year, while female patients were relatively stable It is also worth noting that the early diagnosis rate of colorectal cancer in China and the 5-year survival rate of patients are significantly lower than in Europe and other countries 2.1 Incidence in recent years, the average number of new cases of colorectal cancer in China's tumor registration areas is about 80,000, the incidence rate is 27.47 per 100,000 people, accounting for 9.60% of all new cases of malignant tumors In terms of mortality, the number of deaths from colorectal cancer in the national cancer registration area was 38,264, with a mortality rate of 13.27 per 100,000, accounting for 7.65 per cent of all malignant cancer deaths 2.2 age and regional differences
in terms of age, the incidence and mortality of colorectal cancer were at a lower level before the age of 45, and increased significantly after 45 years of age In urban and rural distribution, both morbidity and mortality rates, urban areas are much higher than rural areas To some extent, this may be related to the awareness and motivation of cancer screening populations in different regions 3 , colorectal cancer monoanti-drugs 3.1 Common colorectal cancer monoantitherapy drugs currently more common colorectal cancer chemotherapy drugs in the market are 5-FU, capheabin, Oshaliplatin, Iliticon, sitoxisimonotag, bevalzumab, panizumab and so on Among the main monoantine drugs are cytoxiid monotonica, belaval monotoidatis, panitoma 3.2 Single anti-drug comparison 3.2.1 mechanism comparison 3.2.2.2 listing situation comparison
we compare the listing of three monoanti-drug drugs and found that the patent of belaval of singj has expired has been listed by a number of imitation enterprises, sitoxixaride and panitamon have no biological similarities listed (Special Note: GENENTECH is a subsidiary of Roche, and Sitoxixis is a product developed by IMCLONE and Merck 4 Comparison of monoanti-drugs in palliative care
According to CSCO (China Cancer Association) colorectal cancer diagnosis and treatment guidelines 2020, removable colorectal cancer generally does not recommend the use of monoantitherapy for complementary treatment, for non-removable colorectal cancer palliative care recommendations as follows: V, Market sales comparison Figure 4 Global sales of colorectal cancer monoantinosis (in millions of dollars) According to IMS data, colorectal cancer three monoantinos sales statistics as shown above, from a global perspective, belaval of singhash accounted for a larger market share, for the other two types of drugs have a huge advantage This can also be seen from the treatment guidelines above recommendations, in palliative care, a class of recommendations are almost all belaval beads monotonidate, side indications that its clinical use and recognition is higher than the other two types of drugs 6 The incidence of primary colorectal cancer in China is on the rise, about 25% of colorectal cancer patients in diagnosis has appeared distant metastasis, in addition, 25% of patients in the course of treatment metastasis, advanced patients have poor prognosis, 5-year survival rate of less than 15% Since the beginning of the 21st century, the development of general foreign science has been rapid, the concept has been updated, and new technologies have emerged, which has been more representative and characteristic in the field of colorectal cancer treatment Although surgery as the core of colorectal cancer treatment has been quite mature, but there are still some patients do not apply for surgical treatment, at this time single resistance in palliative care show great market prospects References: 1 U.S Colorectal Cancer Epidemiological Characteristics Comparison and Prevention Strategy Analysis Chinese Electronic Journal of Colorectal Disease, 2019